BRCA1 mRNA Expression as a Predictive and Prognostic Marker in Advanced Esophageal Squamous Cell Carcinoma Treated with Cisplatin- or Docetaxel-Based Chemotherapy/Chemoradiotherapy

PLoS ONE

Volumn 8, Issue 1, 2013, Pages

  Gao, Yong ^a   Zhu, Jing ^a   Zhang, Xiaohui ^a   Wu, Qingquan ^a   Jiang, Shaoning ^b   Liu, Yangqing ^a   Hu, Zhibin ^a   Liu, Baorui ^a   Chen, Xiaofei ^a  

^a NANJING MEDICAL UNIVERSITY   (China)

^b University of Alabama at Birmingham   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; DOCETAXEL; FLUOROURACIL; MESSENGER RNA;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER GRADING; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CHEMORADIOTHERAPY; DRUG EFFECT; DRUG RESPONSE; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; FEMALE; GENE EXPRESSION; GENETIC ASSOCIATION; GENETIC MARKER; HIGH RISK PATIENT; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NUCLEOTIDE SEQUENCE; OVERALL SURVIVAL; PRIMARY HEALTH CARE; QUANTITATIVE ANALYSIS; RADIATION DOSE FRACTIONATION; REAL TIME POLYMERASE CHAIN REACTION; RISK ASSESSMENT; TREATMENT DURATION; TREATMENT OUTCOME; TUMOR SUPPRESSOR GENE;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRCA1 PROTEIN; CARCINOMA, SQUAMOUS CELL; CHEMORADIOTHERAPY; CISPLATIN; ESOPHAGEAL NEOPLASMS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; OUTCOME ASSESSMENT (HEALTH CARE); PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TAXOIDS; TUMOR MARKERS, BIOLOGICAL;

EID: 84872232062     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0052589     Document Type: Article

References (40)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, et al. (2011) Global cancer statistics. CA Cancer J Clin 61: 69-90.
2. Shibata T, Kokubu A, Saito S, Narisawa-Saito M, Sasaki H, et al. (2011) NRF2 mutation confers malignant potential and resistance to chemoradiation therapy in advanced esophageal squamous cancer. Neoplasia 13: 864-873.
3. Panettiere FJ, Leichman LP, Tilchen EJ, Chen TT, (1984) Chemotherapy for advanced epidermoid carcinoma of the esophagus with single-agent cisplatin: final report on a Southwest Oncology Group study. Cancer Treat Rep 68: 1023-1024.
4. Ajani JA, Ilson DH, Daugherty K, Pazdur R, Lynch PM, et al. (1994) Activity of taxol in patients with squamous cell carcinoma and adenocarcinoma of the esophagus. J Natl Cancer Inst 86: 1086-1091.
5. Ezdinli EZ, Gelber R, Desai DV, Falkson G, Moertel CG, et al. (1980) Chemotherapy of advanced esophageal carcinoma: Eastern Cooperative Oncology Group experience. Cancer 46: 2149-2153.
6. Evans WE, Relling MV, (1999) Pharmacogenomics: translating functional genomics into rational therapeutics. Science 286: 487-491.
7. Alexander BM, Wang XZ, Niemierko A, Weaver DT, Mak RH, et al. (2012) DNA repair biomarkers predict response to neoadjuvant chemoradiotherapy in esophageal cancer. Int J Radiat Oncol Biol Phys 83: 164-171.
8. Harpole DH Jr, Moore MB, Herndon JE 2nd, Aloia T, D'Amico TA, et al. (2001) The prognostic value of molecular marker analysis in patients treated with trimodality therapy for esophageal cancer. Clin Cancer Res 7: 562-569.
9. Joshi MB, Shirota Y, Danenberg KD, Conlon DH, Salonga DS, et al. (2005) High gene expression of TS1, GSTP1, and ERCC1 are risk factors for survival in patients treated with trimodality therapy for esophageal cancer. Clin Cancer Res 11: 2215-2221.
10. Kennedy RD, Quinn JE, Johnston PG, Harkin DP, (2002) BRCA1: mechanisms of inactivation and implications for management of patients. Lancet 360: 1007-1014.
11. Roy R, Chun J, Powell SN, (2012) BRCA1 and BRCA2: different roles in a common pathway of genome protection. Nat Rev Cancer 12: 68-78.
12. Matsuoka S, Ballif BA, Smogorzewska A, McDonald ER 3rd, Hurov KE, et al. (2007) ATM and ATR substrate analysis reveals extensive protein networks responsive to DNA damage. Science 316: 1160-1166.
13. Huen MS, Sy SM, Chen J, (2010) BRCA1 and its toolbox for the maintenance of genome integrity. Nat Rev Mol Cell Biol 11: 138-148.
14. Tassone P, Tagliaferri P, Perricelli A, Blotta S, Quaresima B, et al. (2003) BRCA1 expression modulates chemosensitivity of BRCA1-defective HCC1937 human breast cancer cells. Br J Cancer 88: 1285-1291.
15. Santarosa M, Del CL, Tonin E, Caragnano A, Viel A, et al. (2009) Premature senescence is a major response to DNA cross-linking agents in BRCA1-defective cells: implication for tailored treatments of BRCA1 mutation carriers. Mol Cancer Ther 8: 844-854.
16. Taron M, Rosell R, Felip E, Mendez P, Souglakos J, et al. (2004) BRCA1 mRNA expression levels as an indicator of chemoresistance in lung cancer. Hum Mol Genet 13: 2443-2449.
17. Yun MH, Hiom K, (2009) CtIP-BRCA1 modulates the choice of DNA double-strand-break repair pathway throughout the cell cycle. Nature 459: 460-463.
18. Husain A, He G, Venkatraman ES, Spriggs DR, (1998) BRCA1 up-regulation is associated with repair-mediated resistance to cis-diamminedichloroplatinum(II). Cancer Res 58: 1120-1123.
19. Chabalier C, Lamare C, Racca C, Privat M, Valette A, et al. (2006) BRCA1 downregulation leads to premature inactivation of spindle checkpoint and confers paclitaxel resistance. Cell Cycle 5: 1001-1007.
20. Mullan PB, Quinn JE, Gilmore PM, McWilliams S, Andrews H, et al. (2001) BRCA1 and GADD45 mediated G2/M cell cycle arrest in response to antimicrotubule agents. Oncogene 20: 6123-6131.
21. Quinn JE, Kennedy RD, Mullan PB, Gilmore PM, Carty M, et al. (2003) BRCA1 functions as a differential modulator of chemotherapy-induced apoptosis. Cancer Res 63: 6221-6228.
22. Lafarge S, Sylvain V, Ferrara M, Bignon YJ, (2001) Inhibition of BRCA1 leads to increased chemoresistance to microtubule-interfering agents, an effect that involves the JNK pathway. Oncogene 20: 6597-6606.
23. Byrski T, Gronwald J, Huzarski T, Grzybowska E, Budryk M, et al. (2010) Pathologic complete response rates in young women with BRCA1-positive breast cancers after neoadjuvant chemotherapy. J Clin Oncol 28: 375-379.
24. Byrski T, Huzarski T, Dent R, Gronwald J, Zuziak D, et al. (2009) Response to neoadjuvant therapy with cisplatin in BRCA1-positive breast cancer patients. Breast Cancer Res Treat 115: 359-363.
25. Weberpals JI, Tu D, Squire JA, Amin MS, Islam S, et al. (2011) Breast cancer 1 (BRCA1) protein expression as a prognostic marker in sporadic epithelial ovarian carcinoma: an NCIC CTG OV.16 correlative study. Ann Oncol 22: 2403-2410.
26. Carser JE, Quinn JE, Michie CO, O'Brien EJ, McCluggage WG, et al. (2011) BRCA1 is both a prognostic and predictive biomarker of response to chemotherapy in sporadic epithelial ovarian cancer. Gynecol Oncol 123: 492-498.
27. Weberpals J, Garbuio K, O'Brien A, Clark-Knowles K, Doucette S, et al. (2009) The DNA repair proteins BRCA1 and ERCC1 as predictive markers in sporadic ovarian cancer. Int J Cancer 124: 806-815.
28. Shim HJ, Yun JY, Hwang JE, Bae WK, Cho SH, et al. (2010) BRCA1 and XRCC1 polymorphisms associated with survival in advanced gastric cancer treated with taxane and cisplatin. Cancer Sci 101: 1247-1254.
29. Wei J, Costa C, Ding Y, Zou Z, Yu L, et al. (2011) mRNA expression of BRCA1, PIAS1, and PIAS4 and survival after second-line docetaxel in advanced gastric cancer. J Natl Cancer Inst 103: 1552-1556.
30. Wang L, Wei J, Qian X, Yin H, Zhao Y, et al. (2008) ERCC1 and BRCA1 mRNA expression levels in metastatic malignant effusions is associated with chemosensitivity to cisplatin and/or docetaxel. BMC Cancer 8: 97.
31. Rosell R, Perez-Roca L, Sanchez JJ, Cobo M, Moran T, et al. (2009) Customized treatment in non-small-cell lung cancer based on EGFR mutations and BRCA1 mRNA expression. PLoS One 4: e5133.
32. Leichman L, Berry BT, (1991) Experience with cisplatin in treatment regimens for esophageal cancer. Semin Oncol 18: 64-72.
33. Ilson DH, Ajani J, Bhalla K, Forastiere A, Huang Y, et al. (1998) Phase II trial of paclitaxel, fluorouracil, and cisplatin in patients with advanced carcinoma of the esophagus. J Clin Oncol 16: 1826-1834.
34. Muro K, Hamaguchi T, Ohtsu A, Boku N, Chin K, et al. (2004) A phase II study of single-agent docetaxel in patients with metastatic esophageal cancer. Ann Oncol 15: 955-959.
35. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, et al. (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92: 205-216.
36. Papadaki C, Tsaroucha E, Kaklamanis L, Lagoudaki E, Trypaki M, et al. (2011) Correlation of BRCA1, TXR1 and TSP1 mRNA expression with treatment outcome to docetaxel-based first-line chemotherapy in patients with advanced/metastatic non-small-cell lung cancer. Br J Cancer 104: 316-323.
37. Rosell R, Scagliotti G, Danenberg KD, Lord RV, Bepler G, et al. (2003) Transcripts in pretreatment biopsies from a three-arm randomized trial in metastatic non-small-cell lung cancer. Oncogene 22: 3548-3553.
38. Olaussen KA, Dunant A, Fouret P, Brambilla E, André F, et al. (2006) DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med 355: 983-991.
39. Furuta T, Ueda T, Aune G, Sarasin A, Kraemer KH, et al. (2002) Transcription-coupled nucleotide excision repair as a determinant of cisplatin sensitivity of human cells. Cancer Res 62: 4899-4902.
40. Shen SX, Weaver Z, Xu X, Li C, Weinstein M, et al. (1998) A targeted disruption of the murine Brca1 gene causes gamma-irradiation hypersensitivity and genetic instability. Oncogene 17: 3115-3124.